First Author Year
Study type
Treatments
Patient populations
Patient populations
Sample size
Duration of treatment (Days)
Underlying diseases Age
Zhou-202013 Retrospective cohort study Linezolid Acute myeloid leukaemia (AML) and bacterial infection 45.8 ± 13.6 36 ≥ 7
Vancomycin 47.2 ± 13.1 41
Nalini-200414 Retrospective cohort study Linezolid Gram-positive bacterial orthopedic infections NM 20 Mean 71
Vancomycin NM 52 Mean 42
Stanley-200315 Retrospective cohort study Linezolid Nosocomial pneumonia 58.7% ≥65 356 Mean 10.7±4.4
Vancomycin 51.9% ≥65 330 Mean 10.5±3.7
Nimish-201216 Retrospective cohort study Linezolid Bacterial infection 68.5 ± 12.4 251 Mean 10
Vancomycin 68.6 ± 13.3 251 Mean 7
Satoshi-201317 Retrospective cohort study Linezolid Severe infections 68.0±15.4 91 7.0±5.8
Vancomycin 64.0±14.1 160 10.0±11.4
Daniel-201118 Cross-sectional study Vancomycin Bacterial infection 50.6 98 9.7(95%CI: 8.0-11.7)